Tacti-003: a randomized phase Iib study of eftilagimod alpha (Soluble Lag-3 Protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
Authors
Brana, I.Cheshuk, V.
Kristensen, C. A.
Ortega, M. E.
Sautois, B.
Lopez-Pousa, A.
Christian, J.
Lybaert, W.
Peguero, J.
Park, J.
Metcalf, Robert
Nabell, L.
de Speville, B. D.
Casadevall, J. R.
Rivas, A. S.
Forster, M.
Triebel, F.
Affiliation
Vall d’Hebron Institute of Oncology,B arcelona, SpainIssue Date
2022
Metadata
Show full item recordCitation
Brana I, Cheshuk V, Kristensen CA, Ortega ME, Sautois B, Lopez-Pousa A, et al. Tacti-003: A Randomized Phase Iib Study of Eftilagimod Alpha (Soluble Lag-3 Protein) and Pembrolizumab as First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Journal for immunotherapy of cancer. 2022 Nov;10:A705-A. PubMed PMID: WOS:000919423400634.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2022-SITC2022.0675Additional Links
https://dx.doi.org/10.1136/jitc-2022-SITC2022.0675Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2022-SITC2022.0675